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Background
While significant advances have been made in uncovering the aetiology of Alzheimer's disease and related
dementias at the genetic level, molecular events at the epigenetic level remain largely undefined. Emerging
evidence indicates that small non-coding RNAs (sncRNAs) and their associated RNA modifications are important
regulators of complex physiological and pathological processes, including aging, stress responses, and epigenetic
inheritance. However, whether small RNAs and their modifications are altered in dementia is not known.
Methods
We performed LC-MS/MS–based, high-throughput assays of small RNA modifications in post-mortem samples
of the prefrontal lobe cortices of Alzheimer's disease (AD) and control individuals. We noted that some of the AD
patients has co-occurring vascular cognitive impairment-related pathology (VaD).
Findings
We report altered small RNA modifications in AD samples compared with normal controls. The 15–25-nu-
cleotide (nt) RNA fraction of these samples was enriched for microRNAs, whereas the 30–40-nt RNA fraction was
enriched for tRNA-derived small RNAs (tsRNAs), rRNA-derived small RNAs (rsRNAs), and YRNA-derived small
RNAs (ysRNAs). Interestingly, most of these altered RNA modifications were detected both in the AD and AD
with co-occurring vascular dementia subjects. In addition, sequencing of small RNA in the 30–40-nt fraction
from AD cortices revealed reductions in rsRNA-5S, tsRNA-Tyr, and tsRNA-Arg.
Interpretation
These data suggest that sncRNAs and their associated modifications are novel signals that may be linked to
the pathogenesis and development of Alzheimer's disease.
Fund
NIH grants (R01HL122770, R01HL091905, 1P20GM130459, R01HD092431, P50HD098593, GM103440),
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1. Introduction
Alzheimer's disease (AD) and severe vascular cognitive impairment,
also known as vascular dementia (VaD), are two of the most common
types of dementia. They are characterized by cognitive impairment and
neuropathology caused by neurotoxic forms of amyloid beta peptide,
loss of synapses and neuronal function and, ultimately, significant
neuronal loss. The aetiology of these forms of dementia is still not fully
understood.(Panza et al., 2019)
Recent studies have highlighted epigenetic changes associated with
aging or acquired through interactions with the environment as im-
portant risk factors for dementia, reflecting the fact that causative gene
mutations are rare and are only present in a very small percentage of
dementia patients. RNA modification is one of the most recently
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discovered epigenetic-mediated mechanisms for regulating physiolo-
gical and pathological processes. Small RNA modifications, particularly
those involving microRNAs (miRNAs)(Hébert et al., 2013; Lugli et al.,
2015) and transfer RNA-derived small RNAs (tsRNAs), have attracted
considerable recent attention for their potential clinical relevance and
possible use as diagnostic markers or therapeutic targets of diseases.
(Zhang et al., 2016; Chen et al., 2016a; Schimmel, 2018) To date,
evidence for changes in small RNA modifications in dementia is lacking.
Thus, to gain insights into possible new mechanisms and identify po-
tential biomarkers for dementia, we undertook an exploratory study to
profile small RNA expression and modification status in dementia.
In this report, we profiled small RNA modifications in post-mortem
samples of human brain cortical tissue from patients with clinically and
pathologically diagnosed AD and control individuals. To simulta-
neously detect and quantify 16 types of RNA modifications(Chen et al.,
2016b; Zhang et al., 2018) in different small RNA fractions [15–25
nucleotides (nt), 30–40 nt] from AD patients and control individuals,
we used high-throughput liquid chromatography-tandem mass spec-
trometry (LC-MS/MS). We also profiled the composition of small RNAs
in AD and control subjects using small RNA sequencing. These ex-
ploratory examinations revealed distinct sncRNA expression and RNA
modification signatures between AD and controls, suggesting that these
small RNAs are novel factors associated with the pathogenesis and/or
progression of AD.
2. Materials and methods
2.1. Human subjects for RNA modification assays
A total of 34 post-mortem brain prefrontal lobe cortex samples from
AD patients (n = 27) and control human subjects (n = 7) were col-
lected by post-mortem autopsy, snap-frozen, and stored in liquid ni-
trogen. The time between biospecimen acquisition and analysis ranged
from 5 to 30 years, according to the Brain Bank database. Biospecimens
were shipped on dry ice. Information from clinical and pathology re-
ports was obtained from the brain bank database, developed as de-
scribed.(Hyman et al., 2012) On the basis of their clinical diagnosis,
subjects were first categorized into two groups: no significant ab-
normalities (control) and AD. We realized that some AD patients had
co-occurring vascular dementia. This type of patient usually has a more
rapid course of disease clinically. We thus further divided the AD pa-
tients into AD without VaD (AD-w/o-VaD, n = 18) and AD with VaD
(AD-w-VaD, n = 9) for the purpose of analysis. Subjects in the AD-w-
VaD group were clinically diagnosed with clear AD tau pathology and
Aβ plaques in post-mortem analysis by the UK Brain Bank, and a neu-
ropathological report of AD. Subjects were selected according to their
confirmed clinical and pathological diagnosis as AD or normal, and
were obtained from the Human Tissue Authority-licensed South West
Dementia Brain Bank http://www.bristol.ac.uk/translational-health-
sciences/research/neurosciences/research/dementia/swdbb/, accessed
on March 24th, 2020). detailed information of these subject is also
summarized in Supplemental Table S1. University of Bristol, with tissue
bank ethics approval from the South West–Central Bristol Research
Ethics Committee. Clinical and pathological data included patient his-
tory, diagnosis and medications; pathological reports were available for
retrospective analysis. Patients' personal information has been anon-
ymized. Data and tissues for this study were collected between 1989
and 2015. The Research Integrity Offices at the University of Nevada,
Reno, and University of Bristol have determined that this project
complies with human research protection oversight by the Institutional
Review Board.
2.2. Isolation of total RNA from the human prefrontal cortex
Total RNA was isolated from 100 mg of human prefrontal tissues
using the TRIzol reagent (Thermo Fisher Scientific, Inc. Waltham, MA,
USA), as described by the manufacturer. RNA quantity was evaluated
using a NanoDrop 2000 microvolume spectrophotometer (Thermo
Fisher). RNA samples were stored at−80 °C until analysis. Researchers
performing small RNA sequencing and RNA modifications assays on
RNA samples were blinded to diagnosis and group-identifying in-
formation.
2.3. Small RNA sequencing
Ten RNA samples from prefrontal lobe cortexes of control subjects
and AD patients were submitted to BGI (Cambridge, MA, USA) for se-
quencing of 15–40-nt small RNAs. The number of clean reads varied
from 30 M to 40 M across all samples. The Q20 score was greater than
99·5% for all samples. Raw sequencing data for each sample were
processed and analysed using our newly developed computational fra-
mework, SPORTS1·010 (https://github.com/junchaoshi/sports1.0),
which is designed to optimize the annotation and quantification of non-
canonical small RNAs (e.g., tsRNAs) in small RNA sequencing data.
Sequencing adapters were removed, after which reads with lengths
outside of the defined range and those with nucleotides other than
ATUCG were discarded. Clean reads were mapped against the pre-
compiled human small RNA annotation database (https://github.com/
junchaoshi/sports1.0/blob/master/precompiled_annotation_database.
md). Small RNAs 15–25 and 30–40 nt in length were summarized se-
parately.
2.4. Small RNA purification and analysis of RNA modifications using LC-
MS/MS
Standardized ribonucleoside preparations, small RNA purification,
and LC-MS/MS-based analysis of RNA modifications in RNA samples
were performed as previously described.(Zhang et al., 2018) Purified
small RNAs (100–200 ng) from human brain samples were digested as
input and loaded onto a ThermoFisher Vantage Quadrupole mass
spectrometer connected to a Thermo Ultimate 3000 UHPLC system
equipped with an electrospray ionization source. The MS system was
operated in positive ion mode using a multiple reaction monitoring
(MRM) approach. LC-MS/MS raw data were acquired using Xcalibur
Workstation software and were processed using Xcalibur QuanBrowser
for quantification of modified ribonucleoside concentrations. We totally
performed 34 samples. However, during the analysis of the mass
spectrometry data, we exclude data points when the signal peak is not
unique (e.g. two peaks, elevated baseline), or drifting off the detection
time predetermined by each standardized ribonucleoside, which re-
sulted in inaccurate reading (or loss of reading) of the examined signal.
The percentage of each modified ribonucleoside was normalized to the
total amount of quantified ribonucleosides containing the same nu-
cleobase, an approach that decreases/eliminates errors caused by
sample loading variation. For example, the percentage of m5C = mole
concentration (m5C)/mole concentration (m5C + Cm + C + ac4C).
Fold-changes in RNA modifications between different groups were
calculated based on the percentage of modified ribonuclosides. Brain
RNAs 15–25 and 30–40 nucleotides (nt) in length were examined.
2.5. Statistical analysis
Data are presented as means± SEM and were plotted using Prism8
software (GraphPad, La Jolla, CA, USA). Differential expression ana-
lyses were performed using the edgeR tool (pmid: 19910308), control-
ling for age and sex. RNAs with a false discovery rate < 10% were
deemed to be differentially expressed. RNA modification levels among
groups were compared using a linear model that controls for age and
sex. Student t-test or Ordinary One-way ANOVA with post hoc
Bonferroni correction was used as appropriate for comparisons among
groups. A P-value< 0·05 was considered statistically significant.
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3. Results
3.1. Participant characteristics
As summarized in Tables 1 and 2, patients and control individuals
were similar in terms of age. Almost all patients were White/European
except for one patient whose race was unknown. There were slightly
more males (58·8%) than females (41·2%). As expected, brain weight
was significantly lower in AD (P= 0·0099) compared with the controls
(Table 1). This phenomenon persisted when we subdivided the AD into
(AD-w/o-VaD) (P = 0·018) when compared with controls; however,
there was no significant difference between AD-w-VaD and controls for
the brain weight (Table 2). No significant differences were observed for
the brain pH and post-mortem delay time among groups.
3.2. Altered small RNA modification profiles in the cerebral cortex of AD
patients
To systemically analyse small RNA expression and modification
profiles, we collected the 15–40-nt RNA fraction from the brain frontal
lobe cortex for small RNA sequencing as we previously described(Chen
et al., 2016b; Zhang et al., 2018), and then performed bioinformatic
analyses using our recently developed software, SPORTS1.0.10 In ad-
dition, 15–25-nt and 30–40-nt RNA fractions were collected for high-
throughput examination of RNA modification by LC-MS/MS (Supple-
mental Fig. S1).(Chen et al., 2016b; Shi et al., 2018) These analyses
resulted in the identification and quantification of 16 types of RNA
modifications.
In the 15–25-nt RNA fraction from the cortex of AD brains (Fig. 1A),
we found an increase in 2’-O-methylcytidine (Cm), 7-methylguanosine
(m7G), 2’-O-methylguanosine (Gm), and significant reductions in
N2,N2,7-trimethylguanosine (m2,2,7G) and N2,N2-dimethylguanosine
(m2,2G), compared with controls (Fig. 1B and C). Other RNA mod-
ifications that were not significantly different among groups were also
detected and are shown in Supplemental Fig. S2. Since AD Patients with
co-occurring several vascular cognitive impairment-related pathologies
(e.g. VaD) tend to have a more rapid course of disease clinically.
(Iadecola, 2013) We further test whether these patients have a distinct
difference at RNA modifications. To this end, we divided AD patients
into two groups, the AD-w/o-VaD and AD-w-VaD and performed fur-
ther analysis. We found that both AD-w/o-VaD group and AD-w-VaD
group showed similar trends in RNA modification changes when com-
pare to the normal subjects, but some RNA modifications cannot reach
statistical significance when the two groups are divided (Fig. 2), pos-
sibly due to decreased sample sized in both groups.
In the 30–40-nt small RNA fraction from the cortex of AD brains
(Fig. 3A), we found significantly higher levels of Cm, 2’-O-methylur-
idine (Um) and 7-methylguanosine (m7G) modifications, and reduc-
tions in 1-methylguanosine (m1G), m2,2,7G and pseudouridine (psi or
Ψ) modifications compared with controls (Fig. 3B and C). Other RNA
modifications detected in this 30–40-nt fraction that did not exhibit
significant differences among groups are shown in Supplemental Fig.
S3. When further divided AD into with or without VaD (Fig. 4), we
found that AD-w/o-VaD maintained significant changes in most of these
RNA modifications. One the other hand, the AD-w-VaD group main-
tained the same trend but did not reach significant difference in most of
the RNA modifications compared with the controls possibly due to the
small sample size; however, there was no difference between the AD-w-
VaD and the AD-w/o-VaD suggesting the similar expression profile.
3.3. Altered 30–40-nt small RNA expression profiles in the cerebral cortex
of AD patients
To systemically analyse small RNA expression profiles, we collected
the 15–40-nt fraction from the brain frontal lobe cortex of AD patients
and controls for small RNA sequencing, as we previously described
(Chen et al., 2016b; Zhang et al., 2018), and then performed bioin-
formatic analyses using our recently developed software, SPORTS1·010.
Our RNA-seq analysis showed that the 15–25-nt RNA population was
predominantly miRNAs (Fig. 5A) in both the AD and control samples;
we did not find significant differences in specific small RNA sequences
in this fraction between AD and control samples (data not shown).
Whereas the expression profile of the small RNA population in the
30–40-nt fraction showed more dynamic changes. (Fig. 5B-E). Our
RNA-seq data revealed three major subtypes in the 30–40-nt fraction,
namely tRNA-derived small RNAs (tsRNA), rRNA-derived small RNAs
(rsRNAs) and Y RNA-derived small RNAs (ysRNAs); other un-annotated
RNAs were also found (Fig. 5B). Although there were trends toward an
increase in tsRNAs and a reduction in ysRNAs in AD patients, these
differences did not reach statistical significance. Interestingly, in the
30–40-nt fraction, we found a significant reduction in rsRNA-5S, tsRNA-
Tyr and tsRNA-Arg fragments in AD patients compared with controls
(Fig. 5C–E).
4. Discussion
Emerging evidence shows that small RNAs, including miRNAs,
tsRNAs and piwi-interacting RNAs, harbour a diversity of RNA mod-
ifications.(Roundtree et al., 2017) The physiological and pathological
importance of these small, non-coding RNA modifications has only re-
cently begun to emerge, as highlighted by studies revealing their active
involvement in stress responses, metabolism, immunity, and epigenetic
inheritance of environmentally acquired traits.(Zhang et al., 2016;
Table 1
Characteristics of study subjects for controls and AD.
No abnormalities (CONT) Alzheimer disease (AD)
Demographics
Total patients (n) 7 27
Sex, male/female 5/2 15/12
Ethnicity
White/unknown 6/1 27/0
Age (years) 85·4 ± 2·6 78·1 ± 2·0
Brain
Weight (g) 1286 ± 34·3 1148 ± 24·3 **
PH 6·03 ± 0·08 6·08 ± 0·07
Post-Mortem Delay Time 41·2 ± 4·9 40·8 ± 4·5
Values are means± SE, where appropriate. *p < 0·05, vs. control patients;
Student t-test.
Table 2
Characteristics of study subjects for controls, AD with or without VaD.
No abnormalities
(CONT)
Alzheimer disease
without vascular
dementia (AD-w/o-
VaD)
Alzheimer disease
with Vascular
dementia AD-w-
VaD
Demographics
Total patients (n) 7 18 9
Sex, male/
female
5/2 9/9 6/3
Ethnicity
White/unknown 6/1 18/0 9/0
Age (years) 85·4 ± 2·6 77·3 ± 2·6 79·6 ± 2·5
Brain
Weight (g) 1286 ± 34·3 1130 ± 33 * 1180 ± 33·4
PH 6·03 ± 0·08 6·15 ± 0·09 5·96 ± 0·08
Post-Mortem
Delay Time
41·2 ± 4·9 36·9 ± 5·4 48·5 ± 7·6
Values are means± SE, where appropriate. *p < 0·05, vs. control patients;
one-way ANOVA with Bonferroni correction.
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Lovell et al., 2011; Pietrzak et al., 2011) RNA modifications have re-
cently been detected in the nervous system, where they are involved in
the regulation of cortical differentiation, behaviour, and brain
functions.(Satterlee et al., 2014; Jung and Goldman, 2018) However, to
our knowledge, there have been no reports on the status of small RNA
modifications in AD or VaD to date.
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Fig. 1. Small RNA modifications in the 15–25-nt fraction from samples of the prefrontal lobe cortex of dementia patients. (A) Representative image showing
purification of 15–25-nt small RNAs for the analysis of RNA modifications. (B) Increases in 2’-O-methylcytidine (Cm) 7-methylguanosine (m7G), 2’-O-methylgua-
nosine (Gm), and 3-Methylcytidine(m3C) modifications. (C) Reductions in N2,N2,7-trimethylguanosine (m2,2,7G) and N2,N2-dimethylguanosine (m2,2G) modifications
in the cortex of AD compared with CONT subjects (each dot in the figure represents value from one independent sample); *P < 0·05;**P < 0·01 vs. CONT by
Student t-test.
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The current study showed intriguing differences in small RNA-
modification signatures between AD patients and control subjects,
suggesting an association and possible contribution of such modifica-
tions to the pathogenesis and/or progression of AD. Notably, most of
the altered RNA modifications were observed in the AD with and
without VaD, providing molecular evidence for potential distinct sig-
natures for AD patients. In the last three decades, dementia research has
demonstrated significant overlaps between AD and VaD in terms of
clinical symptoms, risk factors, and post-mortem brain autopsy find-
ings.(Ravona-Springer et al., 2003; Mirra et al., 1991; Meyer et al.,
2002) Therapeutically, drugs that enhance cholinergic activity are as
effective in patients suffering from VaD as they are in AD patients.
(Erkinjuntti et al., 2002) More recently, drugs that have traditionally
been used for cardiovascular diseases, especially renin-angiotensin
system blockers, have shown benefits not only in VaD patients, but also
in AD patients.(Zhuang et al., 2016; Chou and Yeh, 2014; Gebre et al.,
2018) However, the molecular pathogenesis of AD with co-occurring
sever vascular cognitive impairment remains incompletely understood.
It is however worth highlighting that patients with AD and co-occurring
severe Vascular Cognitive Impairment-related pathology (e.g. VaD)
tend to have a more rapid course of disease clinically because of the co-
occurrence of heightened cerebrovascular disease and hypoxia and re-
lated white matter and neuronal damage.(Iadecola, 2013; Vinters et al.,
2018) It was therefore prudent to consider these as a separate group to
explore whether RNA modifications might be more prevalent and thus
potentially associated with the disease. We were not surprised to find
many common signatures among RNA modifications in AD with or
without VaD patients, particularly in the 15–25-nt small RNA mod-
ifications that might contribute to shared mechanisms of dementia
pathology. Yet, the lack of apparent differences between the groups
does suggest, notwithstanding the small sample sizes, that the RNA
modifications may relate more to AD-related processes than neuro-
pathology caused by VaD. Further studies, involving post-mortem
analysis of other cerebrovascular-related diseases and in the absence of
AD or with minimal pathology, and with larger sample size, would be
useful studies to explore this further.
The 15–25-nt RNAs were predominantly miRNAs, whereas 30–40-nt
RNAs were predominantly tsRNAs, rsRNAs and ysRNAs, as demon-
strated by small RNA sequencing. We found changes in RNA-mod-
ification profiles in the AD brain cortex in both fractions of small RNAs.
While the involvement of miRNA in the pathogenesis of AD has been
explored(Hébert et al., 2013; Lugli et al., 2015; Ayers and Scerri, 2018),
the identifications of rsRNAs and ysRNAs in a pathophysiological con-
text has only begun to emerge (Zhang et al., 2018; Hizir et al., 2017;
Zhang et al., 2019a) and has not been studied in AD. The dynamic
expression of these non-canonical small RNAs suggests the possibility of
unidentified biological functions that warrant further investigation
(Kowalski and Krude, 2015; Kabeerdoss et al., 2017), particularly in
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Fig. 2. Small RNA modifications in the 15–25-nt fraction from samples of the prefrontal lobe cortex of dementia patients with and without co-occurring vascular
dementia patients. (A) Increases in 2’-O-methylcytidine (Cm) 7-methylguanosine (m7G), 2’-O-methylguanosine (Gm), and 3-Methylcytidine(m3C) modifications. (B)
Reductions in N2,N2,7-trimethylguanosine (m2,2,7G) and N2,N2-dimethylguanosine (m2,2G) modifications in the cortex of AD-w/o-VaD, AD-w-VaD, and CONT
subjects (each dot in the figure represents value from one independent sample); *P < 0·05;**P < 0·01 vs. CONT by Ordinary One-way ANOVA with post hoc
Bonferroni correction.
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relation to several risk factor genes that have been identified for AD in
the last few decades.(Lambert et al., 2013; Kunkle et al., 2019) This
situation is similar to that for tsRNAs, which have shown recently ex-
panding functions.(Schimmel, 2018; Oberbauer and Schaefer, 2018; Shi
et al., 2019) The novel RNA modifications that showed dynamic
changes in AD patients included Cm, Um, m7G, m1G, m3C, m2, 2G, m2, 2,
7G, and psi. The functions and identities of these small RNA modifica-
tions in AD are not yet understood, but our data suggest that these RNA
modifications in the brain cortex of dementia patients are potentially
important, either as a consequence or an actual cause of pathogenesis.
For example, it has been reported that pH, which may affect the effi-
ciency of related RNA-modifying enzymes and thus contribute to the
RNA modification profile, is lower in the brains of AD patients com-
pared with normal aging controls(Lyros et al., 2020; Ponto et al., 2014).
Although we observed a trend toward lower pH values in post-mortem
samples from AD w/o VaD brains, this difference did not reach statis-
tical significance.
tRNA-derived small RNAs are reported to contribute to multiple
pathological processes, including cancer, viral infection, and age-re-
lated neurodegenerative diseases.(Zhang et al., 2016) In the
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senescence-accelerated mouse prone 8 (SAMP8) model, which mimics
age-related neuro-disorders such as AD and Parkinson's disease, tsRNAs,
including tsRNA-Tyr and tsRNA-Arg, in brain tissue are dysregulated
compared with normal brain tissue. The targets of these dysregulated
tsRNAs are enriched in neurodevelopment pathways such as synapse
formation.(Zhang et al., 2019b) In addition, knockout of the RNA ki-
nase, CLP1, in mice leads to progressive loss of motor neuron function
in association with the accumulation of tsRNAs derived from Try-tRNA
and Arg-tRNA. (Hanada et al., 2013; Schaffer et al., 2014) These tsRNAs
sensitize motor neurons to oxidative stress-induced cell death, sug-
gesting that tsRNAs are involved in normal motor neuron functions and
responses to oxidative stress.(Hanada et al., 2013) A similar phenom-
enon was reported in a human neurological disease cohort, and it was
shown that transfection of small RNAs derived from 5′ Tyr-tRNA can
protect CLP-mutant cells from oxidative stress-induced cell death.
(Schaffer et al., 2014) In our study, the decrease in 5’tsRNA-Tyr in AD
subjects may confer greater vulnerability to oxidative stress on neurons.
Interestingly another report showed that the expression of 5S rRNA and
levels of oxidized 5S rRNA are dynamically modulated in AD's subjects
(Ding et al., 2012), findings that may be related to the biogenesis of
rsRNAs and could explain alterations of rsRNA-5S in the AD group in
the current study.
Whether the changes in small RNAs and RNA modifications
observed here represent drivers or outcomes of AD remains unknown.
In our study, the sample number from the control and patient groups is
relatively small, which prevent deeper analyses to consider other fac-
tors such as ages, NFT pathology stage, and PMI. One limitation of the
current study is the prolonged PMI in some of the brain samples as we
have no access to adequate number of samples with shorter PMI
(e.g.< 24 h PMI). Another potential limitation of our study is the
prolonged storage time in some of the tissues, as long-term storage
might affect the RNA modification results. To examine this possibility.
We performed principle components analysis (PCA), which converts the
observations of possibly correlated variables (RNA modifications) into a
set of values of linearly uncorrelated variables. This analysis of the
27 CE samples ranging from 1985 to 2015 does not support this pos-
sibility that storage time affects RNA modification as showed in
Supplemental Fig. S4. This result support the conclusion that the de-
tected changes in RNA modifications indeed represent intrinsic differ-
ence in the AD samples and the storage time is not a major contributing
factor on the result.
In summary, the current pioneer study based on limited sample
numbers have revealed that RNA modifications in the sncRNAs are
associated with AD, although the precise meaning of each of these
changes in terms of their specific functions awaits discovery. Future
efforts to pinpoint the locations of these modifications in each sncRNA
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population and identify enzymes involved in their regulation would be
invaluable(Lyons et al., 2018; Frye et al., 2018) and will open new
avenues for dissecting the nature of dementia pathology.
Research in context
Evidence before this study
Alzheimer's disease (AD) and vascular dementia (VaD) are marked
by cognitive impairment and neuropathologies caused by significant
neuronal death. Associated gene mutations are rare in subjects with
dementia, and the aetiology of these diseases is still not completely
understood. Recent emerging evidence suggests that epigenetic changes
are risk factors for the development of dementia. However, studies
assessing small RNA modifications—one of the features of
epigenetics—in dementia are lacking.
Added value of this study
We used high-throughput liquid chromatography-tandem mass
spectrometry and small RNA sequencing to profile small RNA mod-
ifications and the composition of small RNAs in post-mortem samples of
the prefrontal cortex of AD and control subjects. We detected and
quantified 16 types of RNA modifications and identified distinct small
non-coding RNAs and modification signatures in AD subjects compared
with controls.
Implications of all the available evidence
This study identified novel types and compositions of small RNA
modifications in the prefrontal cortex of AD patients compared with
control subjects in post-mortem samples. The cellular locations of these
RNA modifications and whether they are drivers or outcomes of AD are
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still not known. However, results from the present study may open new
possibilities for dissecting the dementia pathology.
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